AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...